You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Expert Perspectives on AL Amyloidosis: Timely Identification for Improved Outcomes

  • Authors: Ray Comenzo, MD; Angela Dispenzieri, MD; Ronald Witteles, MD
  • CME / ABIM MOC / CE Released: 4/29/2021
  • Valid for credit through: 4/29/2022, 11:59 PM EST
Start Activity

Target Audience and Goal Statement

This activity is intended for cardiologists, nephrologists, hematologists, primary care physicians, and nurses.

The goal of this activity is to educate clinicians about amyloid light chain (AL) amyloidosis characteristics and the importance of coordinating timely care with the interprofessional team.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • The clinical presentation of AL amyloidosis
    • Data for emerging and new therapies for the treatment of AL amyloidosis
  • Have greater competence related to
    • The diagnostic evaluation of patients who present with symptoms consistent with AL amyloidosis


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Ray Comenzo, MD

    Director, John C. Davis Myeloma & Amyloid Program
    Professor, Tufts University School of Medicine in Boston, Massachusetts


    Disclosure: Ray Comenzo, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie/Genentech; Caelum/Alexion; Janssen; Karyopharm; Sanofi; Takeda
    Received grants for clinical research from: Caelum/Alexion; Janssen
    Other: Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies. Patent WO2016187546A1

  • Angela Dispenzieri, MD

    Serene and Frances C. Durling Professor of Medicine and of Laboratory Medicine, and Pathology
    Hematology Research Chair
    Mayo Clinic
    Rochester, Minnesota


    Disclosure: Angela Dispenzieri, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alnylam; Intellia; Janssen
    Received grants for clinical research from: Alnylan; Celgene; Janssen; Pfizer; Prothena; Takeda

  • Ronald Witteles, MD

    Professor of Cardiovascular Medicine
    Co-Director, Stanford Amyloid Center
    Stanford University School of Medicine
    Palo Alto, California


    Disclosure: Ronald Witteles, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Alnylam; Eidos; Ionis/Akcaea; Pfizer
    Received grants for clinical research from: Alnylam; Eidos; Ionis/Akcaea; Pfizer


  • Cheryl Perkins, MD, RPh

    Medical Education Director, Medscape, LLC


    Disclosure: Cheryl L Perkins, MD, RPh, has disclosed no relevant financial relationships.

CME, CE Reviewer / Nurse planneri

  • Hazel Dennison, DNP, RN, FNP-BC, CHCP, CPHQ, CNE

    Associate Director, Accreditation and Compliance, Medscape, LLC


    Disclosure: Hazel Dennison, DNP, RN, FNP, CHCP, CPHQ, CNE, has disclosed no relevant financial relationships.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Accreditation Statements


Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Contact This Provider

    For Nurses

  • Awarded 0.50 contact hour(s) of continuing nursing education for RNs and APNs; 0.25 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Expert Perspectives on AL Amyloidosis: Timely Identification for Improved Outcomes

Authors: Ray Comenzo, MD; Angela Dispenzieri, MD; Ronald Witteles, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 4/29/2021

Valid for credit through: 4/29/2022, 11:59 PM EST



ACE-I = angiotensin-converting enzyme inhibitor
AE = adverse event
AL = amyloid light-chain
ARB = angiotensin II receptor blocker
ATTR = amyloid transthyretin
BCD = bortezomib, cyclophosphamide, and dexamethasone
BCMA = B-cell maturation antigen
BM = bone marrow
BMBx = bone marrow biopsy and aspiration
BMDex = bortezomib plus melphalan and dexamethasone
BNP = B-type natriuretic peptide
CAR = chimeric antigen receptor
CHF = congestive heart failure
CR = complete response
CyBorD = cyclophosphamide, bortezomib, and dexamethasone
DARA = daratumumab
Dex = dexamethasone
DGE = dynamic glucose enhanced
DPD = 3,3-diphosphono-1,2-propanodicarboxylic acid
eGFR = estimated glomerular filtration rate
FLC = free light chain
GI = gastrointestinal
H&E = hematoxylin and eosin
ICD = implantable cardioverter-defibrillator
IDE-CEL = idecabtagene vicleucel
IMiD = immunomodulatory imide drug
LC = liquid chromatography
LVH = left ventricular hypertrophy
MALToma = lymphoma involving mucosa-associated lymphoid tissue
MASS-FIX = matrix-assisted laser desorption ionization time-of-flight mass-spectrometry
MGUS = monoclonal gammopathy of undetermined significance
MOD-PFS = major organ deterioration progression-free survival
MRD = minimal residual disease
MRI = magnetic resonance imaging
NT-proBNP = N-terminal pro–B-type natriuretic peptide
NYHA = New York Heart Association
PYP = pyrophosphate
SC = subcutaneous
SIFE = serum immunofixation test
SPIE = serum protein electrophoresis with immunofixation
UIFE = urine immunofixation test
UPIE = urine protein electrophoresis with immunofixation
VGPR = very good partial response
VT = ventricular tachycardia

« Return to: Expert Perspectives on AL Amyloidosis: Timely Identification for Improved Outcomes
  • Print